34 th Annual JP Morgan Healthcare Conference. January 13, 2016
|
|
- Kristopher White
- 5 years ago
- Views:
Transcription
1 34 th Annual JP Morgan Healthcare Conference January 13, 2016
2 SAFE HARBOR Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as may, might, will, should, expect, plan, anticipate, believe, estimate, project, intend, future, potential, or continue, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical and clinical studies and our research and development programs, our ability to advance ETC-1002 into, and successfully complete, clinical studies, and the timing or likelihood of regulatory filings and approvals are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These statements are also subject to a number of material risks and uncertainties that are described in the preliminary prospectus supplement and the accompanying prospectus. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors, or representatives, including the underwriters of this offering, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. 2
3 BEMPEDOIC ACID: LOWERING LDL-C A DIFFERENTIATED ORAL THERAPY Pioneering a differentiated oral therapy for hypercholesterolemia Works like a statin ; but with reduced potential for muscle-related side effects Targeting statin intolerance in patients with elevated LDL-C, a high unmet medical need ETC-1002 (bempedoic acid) lowers elevated LDL-C Up to 30% as monotherapy and 50% in combination with ezetimibe Incremental 24% LDL-C lowering when added to stable statin therapy Lowers high-sensitivity C-reactive protein (hscrp) up to 44% Appears safe and well tolerated Continuing progress on Phase 3 global development plans Robust Phase 1 & 2 program completed in >1,000 patients Phase 3 global development plans to be formalized and communicated 1H
4 INVESTMENT HIGHLIGHTS Phase 3 program initiated with launch of 040 long-term safety study First-in-class ACL-inhibitor (ACLi), inhibiting cholesterol biosynthesis Designed to significantly lower elevated levels of LDL-C with reduced potential for muscle-related side effects Compelling, positive clinical results in Phase 1 and 2 studies Appears safe and well-tolerated Bempedoic acid addresses high unmet medical need Currently, no approved therapies for statin intolerance in the US Large and growing market opportunity 3.5M statin intolerant patients in US represents an estimated $7B opportunity Strong financial position Well-funded with ~$300M in cash Experienced management team Prior success in development and approval of lipid regulating drugs 4
5 BEMPEDOIC ACID MOA: ACL INHIBITION INHIBITS CHOLESTEROL BIOSYNTHESIS VIA INHIBITION OF ATP CITRATE LYASE (ACL) Bempedoic acid is an oral, once-daily, small molecule targeting the well-known cholesterol biosynthesis pathway; works like a statin to up-regulate LDL-receptors, lower plasma LDL-C levels and lower hscrp, but with reduced potential for muscle-related side effects. 5 5
6 Cardiovascular Disease Cancer Pulmonary Disease Accidents Alzheimer's Disease CARDIOVASCULAR DISEASE #1 CAUSE OF DEATH IN THE US Top 5 Causes of Death 80M people at risk of cardiovascular disease ~800,000 deaths annually Recent guidelines emphasize need to manage CV risk in even more patients 6 Source: NIH
7 LOWERING LDL-C DECREASES CV RISK ELEVATED LDL-C IS THE #1 MODIFIABLE LIPID RISK FACTOR IMPROVE-IT 7
8 UNMET (RESIDUAL) NEEDS IN LDL-C LOWERING 3.5M PATIENTS UNABLE TO TOLERATE ANY LEVEL OF STATIN THERAPY Statin Intolerance is an estimated $7B opportunity Statin Intolerant; Patients for whom maximally tolerated statin (MTS) is no statin therapy at all 8 Sources: NHANES, Source Health Analytics, NCEP ATP III guidelines, Esperion analysis
9 STATIN INTOLERANCE INCREASINGLY ATTRACTIVE High unmet medical need Estimated 3.5 million SI patients in the US No approved therapies for SI in the US: new therapies urgently needed Patients who can t/won t take statins have very high LDL-C levels Baseline LDL-C levels for SI patients in clinical trials mg/dl Liver-specific and differentiated MOA Bempedoic acid is a pro-drug that inhibits ACL Conversion to active drug only in liver cells results in reduced potential for muscle-related side effects Phase 2 clinical results strongly support Phase 3 success in SI patients Bempedoic acid well-tolerated in hundreds of SI patients LDL-C lowering of 30%/50% in SI patients as mono/combo therapy Details of the Phase 3 SI program to be formalized Q FDA has already requested that Esperion have a CVOT well underway to support initial approval of an LDL-C lowering label in SI 9 9
10 UNMET (RESIDUAL) NEEDS IN LDL-C LOWERING Esperion Focus Partnership Opportunities Statin Intolerant HeFH ASCVD High LDL-C levels comparable to pre-statin era Pragmatic diagnostic approach used by physicians Low satisfaction level with existing treatment options Patients and physicians actively searching for alternatives POPULATION: 3.5M US PATIENTS Well defined but underdiagnosed population Requires significant effort to raise awareness Population: ~600K US patients Large and diverse population All patients with previous CV event Significant overlap with diabetes population Population: ~10M US patients 10 Source: US NHANES, Decision Resources, Esperion analysis
11 UNMET (RESIDUAL) NEEDS IN LDL-C LOWERING BEMPEDOIC ACID TARGET PATIENT POPULATION Esperion Focus No Statin Some Statin Statin Tolerant DESCRIPTION Patients do not tolerate any dose of statin Patients tolerate low or moderate dose statins Patients are generally tolerant of statins, including high-intensity statins PATIENT POPULATION 10% or 3.5 million patients Estimated additional 10% of patients 80-95% UNMET NEED First-line, low-cost LDL-C lowering Most patients require additional LDL-C lowering ~1/3 of patients require additional LDL-C lowering BEMPEDOIC ACID OPPORTUNITY As oral, once daily monotherapy or addon to ezetimibe As add-on to low or moderate dose statins As add-on to statins No Statin Some Statin Statin Tolerant 11 Source: Maningat and Breslow. NEJM 2011; NLA 2014
12 LSMean (95%Cl) Percent Change From Baseline BEMPEDOIC ACID: SUMMARY OF LDL-C LOWERING 30% LDL-C LOWERING ACROSS ALL COMPLETED STUDIES; ALMOST 50% IN COMBINATION WITH EZETIMIBE Placebo, reference line Monotherapy Combo with ezetimibe ETC-1002 Daily Dose, mg Adapted from Integrated Summary of Efficacy, Table , dated 18May Integrated Phase 2 data includes , -005, -006, -007, -008 and -009
13 DELIVERING POSITIVE RESULTS IN CLINICAL TRIALS CONSISTENT DELIVERY OF SAFETY, TOLERABILITY AND EFFICACY POSITIVE RESULTS: PHASE 1 POSITIVE RESULTS: PHASE 2A 005 STUDY POSITIVE RESULTS: PHASE 2A 007 STUDY POSITIVE RESULTS: PHASE 2B 009 STUDY POSITIVE RESULTS: PHASE 2A 003 STUDY POSITIVE RESULTS: PHASE 2A 006 POSITIVE RESULTS: PHASE 2B 008 POSITIVE RESULTS: PHASE COMPLETION OF ALL NONCLINICAL STUDIES AHA MOA MUSCLE- SPARING DATA & -009 DATA PRESENTATIONS REMOVAL OF PPAR PARTIAL CLINICAL HOLD REMOVAL OF 240 MG PARTIAL CLINICAL HOLD -003 PUBLICATION BALANTYNE et. al., JACC PUBLICATION GUTIERREZ et. al., ATVB PUBLICATION THOMPSON et. al., JCL PUBLICATION THOMPSON et. al., JCL 2016 (in press) 13 References available upon request
14 US REGULATORY ENVIRONMENT FOR LDL-C CLARIFICATION OF APPROVAL REQUIREMENTS HISTORICAL FOCUS CURRENT FOCUS Statins approved for LDL-C lowering based on positive CVOT data from non-statins (cholestyramine, gemfibrozil, niacin) Each new LDL-C lowering drug class is evaluated independently Statin CVOTs consistently showed significant CV risk reduction benefit in all patient populations tested LDL-C lowering hypothesis is valid when reducing elevated LDL-C levels CVOTs as add-on to statin have NOT demonstrated incremental clinical benefit: Fenofibrate: ACCORD (2010) Niacin: AIM-HIGH (2011), HPS2-THRIVE (2012) CETP inhibitors: ILLUMINATE (2006), dal- OUTCOMES (2012), ACCELERATE (2015) All sponsors are expected to demonstrate favorable risk:benefit profile for each new LDL-C lowering drug Changes in regulatory environment evident in recent EMDAC meetings 14 14
15 2016 BEMPEDOIC ACID MILESTONE PREVIEW Q2 16 Mid 16 2H 16 Announce global Phase 3 CLEAR SI development plans Initiate Phase 3 CLEAR SI efficacy studies Initiate SI CVOT Announce top-line results from Phase 2 (035) high-dose statin (HDS) study File IND for the FDC of bempedoic acid and ezetimibe Announce top-line results from Phase 1 PK (037) HDS study 15
16 BEMPEDOIC ACID DEVELOPMENT OPPORTUNITIES Esperion Focus Partnership Opportunities Statin Intolerant Patients Add-on to Statins (in HeFH and ASCVD Patients) No Approved Therapeutic Options in the US Similar to Recently Approved Antibody Therapies 16 16
17 BEMPEDOIC ACID FOCUSED DEVELOPMENT PLAN Phase 3 Program CLEAR (Cholesterol Lowering via ETC-1002, an ACL-inhibiting Regimen) Focused on patients with statin intolerance Long-term safety study (040) initiated with 52 week dosing Additional studies (035, 037) initiated to address specific questions of bempedoic acid in combination with HDS Remainder of Phase 3 program studies to be formalized Q Proposed indications Pursue initial approval for LDL-C reduction in statin intolerant patients Expand label in SI patients with CVOT data for CV Risk Reduction 17 17
18 BEMPEDOIC ACID -040 PHASE 3 STUDY 52 WEEK LONG-TERM SAFETY STUDY: TOP-LINE RESULTS EXPECTED Q Patients at High CV Risk with Hyperlipidemia not Adequately Controlled by Lipid Modifying Therapy Bempedoic acid 180 mg (n=600) Placebo (n=300) 52 Week Treatment Primary Objective Long-term safety and tolerability of bempedoic acid 180 mg versus placebo in high CV risk patients with hyperlipidemia: High CV risk patients who are not at LDL-C goal Maximally tolerated lipid-modifying therapy Limited to include patients on stable low to moderate dose statin therapy Secondary Objective At 12, 24, and 52 weeks, assess: LDL-C, HDL-C, non-hdl-c, total cholesterol and triglycerides Apolipoprotein B (apob) and hscrp 18 18
19 BEMPEDOIC ACID -035 PHASE 2 STUDY HIGH-DOSE STATIN STUDY: TOP-LINE RESULTS EXPECTED MID-2016 Elevated LDL-C Patients While on Stable High-Dose Statin Therapy (Atorvastatin 80mg) 1 week Screening (patients on low, moderate, or high intensity statin therapy at least 4 weeks prior to screening) 4 Week Treatment with 80 mg Atorvastatin (n=60) 4 Week Treatment with 80 mg Atorvastatin + bempedoic acid 180 mg (n=40) or placebo (n=20) Primary Objectives LDL-C lowering efficacy of bempedoic acid 180 mg versus placebo Multiple-dose plasma pharmacokinetics (PK) of atorvastatin 80 mg Secondary Objectives Efficacy of bempedoic acid 180 mg versus placebo Safety and tolerability Steady state plasma PK of bempedoic acid 180 mg 19 19
20 BEMPEDOIC ACID -037 PHASE I STUDY PK STUDY: TOP-LINE RESULTS EXPECTED MID-2016 Phase 1 PK study to assess effects of bempedoic acid on single doses of HDS: 80 mg of atorvastatin 40 mg of simvastatin 80 mg of pravastatin 40 mg of rosuvastatin Statin PK, safety and tolerability will be evaluated Study to initiate in February 2016 with top-line results expected mid
21 PROVEN LEADERSHIP TEAM Tim Mayleben President and CEO Experience Products to Market Narendra Lalwani, PhD, MBA Executive VP, R&D and COO Mary McGowan, MD Chief Medical Officer Roger Newton, PhD, FAHA CSO and Executive Chairman Marianne Andreach Sr. VP, Strategic Marketing Ashley Hall VP, Global Regulatory Affairs Rick Bartram VP, Finance 21
22 INVESTMENT HIGHLIGHTS Phase 3 program initiated with launch of 040 long-term safety study First-in-class ACLi, inhibiting cholesterol biosynthesis Designed to significantly lower elevated levels of LDL-C with reduced potential for muscle-related side effects Compelling, positive clinical results in Phase 1 and 2 studies Appears safe and well-tolerated Bempedoic acid addresses high unmet medical need Currently, no approved therapies for statin intolerance in the US Large and growing market opportunity 3.5M statin intolerant patients in US represents an estimated $7B opportunity Strong financial position Well-funded with ~$300M in cash Experienced management team Prior success in development and approval of lipid regulating drugs 22
23 Q&A
JMP 2017 Life Sciences Conference. Tim Mayleben
JMP 2017 Life Sciences Conference Tim Mayleben PRESIDENT AND CEO JUNE 21, 2017 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationStudy 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
Study 1 (1002-040) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018 1 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE Safe Harbor Forward-Looking Statements These
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationBempedoic Acid / Eze.mibe Combina.on Development & Regulatory Update. June 26, 2017
Bempedoic Acid / Eze.mibe Combina.on Development & Regulatory Update June 26, 2017 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentaoon contain forward-looking statements
More informationEarly Clinical Development #1 REGN727: anti-pcsk9
Early Clinical Development #1 REGN727: anti-pcsk9 July 15, 2010 Neil Stahl, Ph.D. Senior Vice President Research and Development Sciences 1 Safe Harbor Statement Except for historical information, the
More informationIR Thematic Call on Alirocumab. March 31 st, 2014
IR Thematic Call on Alirocumab March 31 st, 2014 Sanofi Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationOppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer
Oppenheimer 29th Annual Healthcare Conference Mark Timney, Chief Executive Officer New York City 20th March 2019 1 Safe Harbor Forward-looking statements Statements contained in this presentation about
More information2/10/2016. Is it Time to Return to Cholesterol Goals for Optimal Patient Management? CON. Disclosures. Stipulations
Is it Time to Return to Cholesterol Goals for Optimal Patient Management? CON Donald M. Lloyd-Jones MD ScMFACC FAHA Eileen M. FoellProfessor Chair, Dept. of Preventive Medicine Senior Associate Dean Director,
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationZafgen PWS Clinical Trial Program Overview. November 16, 2014
Zafgen PWS Clinical Trial Program Overview November 16, 2014 2 Disclaimers Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationResults of ODYSSEY OUTCOMES Trial
Results of ODYSSEY OUTCOMES Trial Evaluation of long-term cardiovascular outcomes after Acute Coronary Syndrome (ACS) during treatment with Praluent (alirocumab) Investor call at ACC, Orlando, March 10,
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationUpdate on inclisiran Discussion of ORION-1 trial
Update on inclisiran Discussion of ORION-1 trial Conference call: March 17, 2017 4:30 pm 5:30 pm, EDT 1 Forward-looking statements Statements contained in this presentation that are not purely historical
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationMadrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial -- Statistically significantly more patients treated with
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationLeaders in Managing Lipids for Improved Cardiovascular Health
Leaders in Managing Lipids for Improved Cardiovascular Health INVESTOR PRESENTATION June 2015 Nasdaq: AMRN Forward-Looking Statement and Disclaimer This presentation contains forward-looking statements,
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationEndoxifen Clinical Update February 1, 2018
Endoxifen Clinical Update February 1, 2018 107 Spring Street Seattle, WA 98104 USA Forward-looking Statements Some of the information presented herein may contain projections or other forward-looking statements
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationAcasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C CaPre(R) Met All Primary and Key Secondary Endpoints Statistically
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationNYSE AMER: MTNB. MAT9001 OVERVIEW. September 2018
NYSE AMER: MTNB www.matinasbiopharma.com MAT9001 OVERVIEW September 2018 1 Forward Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationLDL and the Benefits of Statin Therapy
LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationPamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Jefferies Global Healthcare Conference June 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationVolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused
More informationDeep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City
Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationPurpose: To establish a guideline in order to reduce ASCVD risk based the four identified statin benefit groups
Title: Algorithm Based on AHA-13 Report on Lipids Date Created: 11/30/2015 Date Modified: N/A Date Approved by Board of Directors: 12/08/2015 Clinical Guideline # CGC-CG-12 Purpose: To establish a guideline
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationTransforming Treatment for Migraine. 16 th Annual Needham Healthcare Conference April 4, 2017
Transforming Treatment for Migraine 16 th Annual Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and the accompanying commentary contain certain forward-looking
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): Bempedoic acid (ETC-1002) is an ATP-citrate lyase (ACL) inhibitor that in clinical studies has been shown to decrease plasma LDL cholesterol apparently
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationNext Generation Lipid Modification in Cardiovascular Disease
TM Next Generation Lipid Modification in Cardiovascular Disease Investor Presentation Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements,
More informationPROFOUND MEDICAL CORP.
PROFOUND MEDICAL CORP. Pioneering a new standard of care in the treatment of prostate cancer Forward-Looking Statements This presentation and oral statements made during this meeting regarding Profound
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationNew Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof.
New Lipid Lowering Agents (PCSK9 Inhibitors, Bempedoic Acid, Apabetalone) in the Elderly? The State of the Recent Knowledge Prof. Maciej Banach Łódź, PL According to : Central Intelligence Agency". Retrieved
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationCompany Overview. September 2018 NASDAQ: MDGL
Company Overview September 2018 NASDAQ: MDGL 1 Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More information1 NASDAQ: ATOS WWW. ATOSSAGENETICS. COM 2016, A TOSSA G ENETICS, I NC. A LL R IGHTS R ESERVED. C ORPORATE P RESENTATION M ARCH 20, 2017
1 NASDAQ: ATOS WWW. ATOSSAGENETICS. COM 2016, A TOSSA G ENETICS, I NC. A LL R IGHTS R ESERVED. C ORPORATE P RESENTATION M ARCH 20, 2017 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated March
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationEiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 Eiger
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationIntercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
July 31, 2017 Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update Worldwide net Ocaliva (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationConference Call for Investment Community. Nov 19, 2018
Conference Call for Investment Community Nov 19, 2018 Agenda for Today s Call Topic Safe Harbor Statement Opening Remarks AR101 for Peanut Allergy Speaker Laura Hansen, PhD, VP, Investor Relations Jayson
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More information